Aspire Biopharma Holdings (ASBP) EPS (Basic) (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly EPS (Basic) came in at -$1.22 in Q2 2026, up 23.94% year-over-year from -$0.99 in Q2 2025, and up 94.06% quarter-over-quarter from -$20.57 in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) EPS (Basic) (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EPS (Basic) for 6 consecutive years, with -$1.22 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 23.94% year-over-year to -$1.22 in Q2 2026; TTM through Jun 2026 was -$14.64, a 3.96% increase from a year earlier, with the FY2025 full-year figure at -$12.94, up 78.73% from the prior year.
- EPS (Basic) was -$1.22 for Q2 2026 at Aspire Biopharma Holdings, up from -$20.57 in the prior quarter.
- Over five years, EPS (Basic) peaked at $15.62 in Q2 2023 and troughed at -$20.57 in Q1 2026.
- A 5-year average of -$1.31 and a median of -$1.17 in 2026 frame the typical range for EPS (Basic).
- Across the five-year window, EPS (Basic) jumped 200062.36% in 2022 and tumbled 425.17% in 2024, its largest moves.
- Over 5 years, EPS (Basic) stood at $9.66 in 2022, then tumbled by 106.38% to -$0.62 in 2023, then plunged by 425.17% to -$3.24 in 2024, then slumped by 66.89% to -$5.41 in 2025, then soared by 77.4% to -$1.22 in 2026.
- The last three EPS (Basic) figures came in at -$1.22 (Q2 2026), -$20.57 (Q1 2026), and -$5.41 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.62 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -1.96 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 7.70 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -0.40 |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | -1.22 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.22 |
| Mar 31, 2026 | -20.57 |
| Dec 31, 2025 | -5.41 |
| Sep 30, 2025 | -2.12 |
| Jun 30, 2025 | -1.61 |
| Mar 31, 2025 | -16.83 |
| Dec 31, 2024 | -3.24 |
| Sep 30, 2024 | -1.11 |
| Jun 30, 2024 | -2.85 |
| Mar 31, 2024 | -10.98 |
| Dec 31, 2023 | -0.62 |
| Sep 30, 2023 | -0.31 |
| Jun 30, 2023 | 15.62 |
| Mar 31, 2023 | 12.79 |
| Dec 31, 2022 | 9.66 |
| Sep 30, 2022 | 4.80 |
| Jun 30, 2022 | 0.54 |
| Mar 31, 2022 | -0.16 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | -0.10 |